Medical Condition News

RSS

Behavioral Innovations includes In-home Autism Treatment programs in ABA services at San Antonio

SANBehavioral Innovations, the premier provider of Applied Behavior Analysis (ABA) services for families of children with Autism and other developmental disorders, announces the expansion of its San Antonio services to include In-home Autism Treatment programs and consultation services for schools and professionals.

19 Aug 2010

FDA grants orphan drug designation to ImmunoGen's lorvotuzumab mertansine for small-cell lung cancer

ImmunoGen, Inc., a biotechnology company that develops antibody-based targeted anticancer products, today announced that the US Food and Drug Administration (FDA) has granted orphan drug designation to its lorvotuzumab mertansine (formerly IMGN901) product candidate when used for the treatment of small-cell lung cancer (SCLC).

19 Aug 2010

FDA approves CSL Behring's sBLA to extend shelf life of Hizentra from 18 to 24 months

CSL Behring announced today that the U.S. Food and Drug Administration (FDA) has approved a supplemental Biologics License Application (sBLA) to extend the shelf life of Hizentra®, Immune Globulin Subcutaneous (Human), 20% Liquid, from 18 months to 24 months. Hizentra, the first and only 20 percent subcutaneous immunoglobulin (SCIg) approved in the U.S. by the FDA, is also the first and only SCIg in the U.S. that may be stored at room temperature.

19 Aug 2010

Beltone Electronics launches new generation of wireless hearing instruments

Chicago-based Beltone Electronics recently announced the introduction of the Beltone True™, a new generation of virtually invisible hearing instruments that wirelessly receive sound directly from TV, cell/home phone, stereo, PC, iPod or any audio device via a 2.4 GHz signal.

18 Aug 2010

Bolder BioTechnology receives $600,000 NIH SBIR grant to study long-acting IL-11 analog in ARS

Bolder BioTechnology, Inc. today announced that it has been awarded a Phase I Small Business Innovation Research (SBIR) grant totaling $600,000 from the National Institute of Allergy and Infectious Diseases (NIAID) of The National Institutes of Health (NIH). The grant will be used to demonstrate the feasibility of using our novel, long-acting IL-11 analog to accelerate platelet recovery and improve survival in a mouse model of Acute Radiation Syndrome (ARS).

18 Aug 2010

70% rise in kidney disease in Australia over past 7 years: Report

According to a report released today by the Australian Institute of Health and Welfare (AIHW), with the rise of type II diabetes patients, there is increasing number of hospitalizations related to chronic kidney disease in Australia.

18 Aug 2010

Gene-regulating molecule plays key role in development of Th9 cells linked to chronic respiratory tract illness

Scientists at the University Medical Center of Johannes Gutenberg University Mainz, Germany have taken a further step towards improving our understanding of how asthma develops. These new findings show that the gene-regulating molecule "IRF4" plays a key role in the development of T helper 9 lymphocytes (Th9 cells), which can play a major part in the development of this chronic, inflammatory illness of the respiratory tract.

18 Aug 2010

Intellect Neurosciences locks database of OXIGON Phase 1b clinical trial for Alzheimer's disease

Intellect Neurosciences, Inc. a biopharmaceutical company with an internal preclinical and clinical-stage pipeline and licenses with major pharmaceutical companies covering products in late-stage clinical trials, announced that it has locked the database of the Company's Phase 1b clinical trial for its lead Alzheimer's candidate, OXIGON™ (OX1).

18 Aug 2010

Researchers participate in Alzheimer's Breakthrough Ride to urge Congress make the disease a national priority

This summer, more than 55 researchers participating in the Alzheimer's Breakthrough Ride are cycling relay-style across the country, collecting petition signatures asking Congress to make Alzheimer's disease a national priority. The public response to the petition has been so overwhelming that as the Alzheimer's Breakthrough Riders hit the halfway point in their 67-day route from San Francisco to Washington, D.C. on August 18, they are already more than 80% of the way to their goal of 50,000 signatures.

18 Aug 2010

Wound Management Technologies' CellerateRX introduced at DFWG congress in South Africa

Wound Management Technologies, Inc. announced today that its new international distributor, Spiramed (Pty) Ltd, exhibited its advanced wound care collagen product, CellerateRX® last weekend at the DFWG (Diabetic Foot Working Group) congress in Cape Town and has already planned exhibitions at two additional upcoming conferences. This second meeting of the DFWG congress was attended by over 120 diabetic foot specialists.

18 Aug 2010

Biogen Idec, Knopp Neurosciences enter license agreement for KNS-760704 ALS drug candidate

Biogen Idec and Knopp Neurosciences today announced they have entered into an exclusive, worldwide license agreement under which Biogen Idec will develop and commercialize KNS-760704 (dexpramipexole) for the treatment of amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig's disease, and potentially other indications.

18 Aug 2010

Study on differential aspects of cardiac insufficiency due to high blood pressure amongst women and men

Doctor Elena Zubillaga studied 109 women and 120 men admitted to hospital with a cardiac insufficiency solely due to high blood pressure. More concretely, she analysed the clinical, biochemical and ecocardiographical differences between the patients, depending on their sex. She also made reference to the data provided by serum markers for the metabolism of the collagen in the heart and the systolic function or contraction of the latter, as alterations taking place in the metabolism of myocardial collagen are associated with certain clinical situations.

18 Aug 2010

Maternal stress associated with increased risk of schizophrenia in male offspring

For more than a century, clinical investigators have focused on early life as a source of adult psychopathology. Although the hypothesized mechanisms have evolved, a central notion remains: early life is a period of unique sensitivity during which experience confers enduring effects.

18 Aug 2010

Quark enters licensing option agreement with Novartis for p53 temporary inhibitor siRNA drug QPI-1002

Quark Pharmaceuticals, Inc., a world leader in the discovery and development of RNAi-based therapeutics, today announced that it has granted Novartis an option to obtain an exclusive worldwide license to develop and commercialize its p53 temporary inhibitor siRNA drug QPI-1002, currently the subject of a Phase II clinical trial.

18 Aug 2010

Results from TITAN trial of CARILLON Mitral Contour System to be presented at ESC 2010 Congress

Cardiac Dimensions, an early stage company focused on the development of minimally invasive devices for the treatment of mitral valve disease and congestive heart failure, announced today that the 12-month follow-up results from the TITAN trial of the Company's CARILLON Mitral Contour System will be presented at the European Society of Cardiology 2010 Congress on August 29, 2010 in Stockholm.

18 Aug 2010

FDA grants BSD Medical marketing clearance for MicroThermX Microwave Ablation System

BSD Medical Corporation today announced that the U.S. Food and Drug Administration (FDA) has granted the Company a 510(k) clearance to market its MicroThermX Microwave Ablation System (MTX-180) for ablation of soft tissue. Clearance from the FDA of BSD's 510(k) Premarket Notification submission authorizes the commercial sale of the MTX-180 in the United States. The MTX-180 was designed to provide a higher power, optimized system targeted to the growing therapeutic interventional and surgical oncology market.

18 Aug 2010

FDA grants orphan drug designation to NephRx's lead product NX001

NephRx Corporation today announced that the U.S. Food and Drug Administration has granted orphan drug designation to its lead product NX001 for the prevention of delayed graft function in renal transplant recipients. NX001 is a kidney growth factor peptide that has demonstrated good safety and promising efficacy in two animal models of acute renal failure.

18 Aug 2010

Aggressive children more inclined to misuse drugs

Aggressive and hyperactive boys with low parental monitoring are more likely to befriend deviant peers and become heavy drug users as teens, according to a new study published in the journal Addictive Behaviors. Yet the investigation by scientists from the Universit- de Montr-al and Sainte-Justine University Hospital Research Center found that bad boys can be protected from heavy substance use as teenagers if they are highly monitored and befriend good boys as children.

18 Aug 2010

Stand Up To Cancer prepares for next Team Fundraising Challenge

As part of a new long-term alliance, Stand Up To Cancer is gearing up for its next Team Fundraising Challenge by joining forces with one of television's most popular shows, Survivor on CBS. For the first time ever, Survivor will stand up and issue the "Challenge The Odds" Team Challenge with Stand Up To Cancer Ambassador and winner of Survivor: Africa, Ethan Zohn.

18 Aug 2010

New research explores effects of radiation on human bone after stereotactic radiosurgery

New research holds promise for the thousands of people whose cancer has spread to their bones.A common treatment for such patients is radiation surgery even though very little is known about radiosurgery's impact on bone strength, says Edmond Richer, associate professor of engineering at Southern Methodist University in Dallas.

18 Aug 2010

Medical Condition News

Behavioral Innovations includes In-home Autism Treatment programs in ABA services at San Antonio

FDA grants orphan drug designation to ImmunoGen's lorvotuzumab mertansine for small-cell lung cancer

FDA approves CSL Behring's sBLA to extend shelf life of Hizentra from 18 to 24 months

Beltone Electronics launches new generation of wireless hearing instruments

Bolder BioTechnology receives $600,000 NIH SBIR grant to study long-acting IL-11 analog in ARS

70% rise in kidney disease in Australia over past 7 years: Report

Gene-regulating molecule plays key role in development of Th9 cells linked to chronic respiratory tract illness

Intellect Neurosciences locks database of OXIGON Phase 1b clinical trial for Alzheimer's disease

Researchers participate in Alzheimer's Breakthrough Ride to urge Congress make the disease a national priority

Wound Management Technologies' CellerateRX introduced at DFWG congress in South Africa

Biogen Idec, Knopp Neurosciences enter license agreement for KNS-760704 ALS drug candidate

Study on differential aspects of cardiac insufficiency due to high blood pressure amongst women and men

Maternal stress associated with increased risk of schizophrenia in male offspring

Quark enters licensing option agreement with Novartis for p53 temporary inhibitor siRNA drug QPI-1002

Results from TITAN trial of CARILLON Mitral Contour System to be presented at ESC 2010 Congress

FDA grants BSD Medical marketing clearance for MicroThermX Microwave Ablation System

FDA grants orphan drug designation to NephRx's lead product NX001

Aggressive children more inclined to misuse drugs

Stand Up To Cancer prepares for next Team Fundraising Challenge

New research explores effects of radiation on human bone after stereotactic radiosurgery

The evolution of OCT for retinal imaging and disease intervention

Supercharging Next-Gen Antibody Discovery with AI and High-Throughput Experimentation

Prof. Dr. Kristina Kusche-Vihrog

Latest News